Given the fact that VEGFR2 is expressed by multiple types of immune cells, and tumor cells we have used have limited to no VEGFR2 expression, the efficacy of VEGFR2 inhibition we have shown in breast and colon cancer models is due to dual targeting of tumor endothelium and immune cells. The gene discussed is KDR; the disease is neoplasm.